Acetylsalicylic Acid as an Effective and Safe Basis for Antiplatelet Therapy

A.E. Lievykh, V.I. Mamchur


Data about pharmacodynamics, pharmacokinetics, clinical efficacy and safety of long-term therapy with acetylsalicylic acid (ASA) in patients with cardiovascular diseases are presented in the review paper. The main practical ways to reduce the possible gastrointestinal complications are discussed. Convincing positive results of clinical trials and so-called gastric toxicity of ASA together with the need of prolonged use of the preparation as an antiaggregant were the basis for the appearance of the various do­sage forms of ASA: soluble, with controlled release, enteric-coated, local, buffer, as well as combined agents containing ASA and substances with antacid effect. To date, the most convincing evidence for the efficacy and gastrointestinal safety has been obtained for enteric forms of ASA.


acetylsalicylic acid; efficacy; safety


Антитромбоцитарная терапия ацетилсалициловой кислотой / Под ред. проф. М.Я. Руды. — М., 1998.

Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // BMJ. — 2002. — Vol. 324. — P. 71-86.

Shimokawa T., Smith W.L. Prostaglandin endoperoxide synthase — the aspirin acetylation region // J. Biol. Chem. — 1992. — Vol. 267. — P. 12378.

Михайлова И.Е., Перепеч Н.Б. Ацетилсалициловая кислота: сфера клинического применения и доказательства эффективности // РМЖ. — 2007. — T. 15(22). — C. 1602-1608.

Терещенко С.Н., Джаиани Н.А. Антитромботическая терапия как основа профилактики сердечно-сосудистых осложнений. Фокус на ацетилсалициловую кислоту // Трудный пациент. — 2008. — T. 11(6). — C. 5-10.

Patrono C., Rocca B. Aspirin: promise and resistance in the new millennium // Arterioscler. Thromb. Vasc. Biol. — 2008. — Vol. 28. — P. 25-32.

Patrono C. Aspirin as an antiplatelet drug // N. Engl. J. Med. — 1994. — Vol. 330(18). — P. 1287-1294.

Awtry E.H., Loscalzo J. Aspirin // Circulation. — 2000. — Vol. 101. — P. 1206-1218.

Jakubowski J.A., Stampfer M.J., Vaillancourt R. et al. Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxyge­nase // J. Lab. Clin. Med. — 1986. — Vol. 108. — P. 616-621.

Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 (Second International Study of Infarct Survival) Collaborative Group // Lancet. — 1988. — Vol. 2(8607). — P. 349-360.

Antithrombotic Trialists (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials // Lancet. — 2009. — Vol. 373(9678). — P. 1849-1860.

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the Ame­rican College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee // Circulation. — 2008. — Vol. 117(2). — P. 261-295.

Juul-Muller S., Edvardsson N., Jahnmatz B. et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group // Lancet. — 1992. — Vol. 340(8833). — P. 1421-1425.

Yusuf S., Zhao F., Mehta S.R. et al. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST elevation. The CURE trial investigators // N. Engl. J. Med. — 2001. — Vol. 345(7). — P. 494-502.

Bhatt D.L., Scheiman J., Abraham N.S. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents // J. Am. Coll. Cardiol. — 2008. — Vol. 52(18). — P. 1502-1517.

Лєвих А.Е., Подплетня О.А. Можливості оптимізації антиагрегантних властивостей ацетилсаліцилової кислоти // Фармакологія та лікарська токсикологія. — 2011. — № 5(24). — С. 187-189.

Walker J., Robinson J., Stewart J. et al. Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? // Interact Cardiovasc Thorac Surg. — 2007. — Vol. 6(4). — P. 519-522.

Cole A.T., Hudson N., Liew L.C. et al. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction? // Aliment. Pharmacol. Ther. — 1999. — Vol. 13(2). — P. 187-193.

Dietz R., Rauch B. Leitlinie zur Diagnose und Behandlung der chronischen koronaren Herzerkrankung der Deutschen Gesellschaft fr Kardiologie — Herz- und Kreislaufforschung (DGK) // Z. Kardiol. — 2003. — Vol. 92. — P. 501-521.

Collaborative Group of the Primary Prevention Project. Lowdose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice // Lancet. — 2001. — Vol. 357. — P. 89-95.

Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2019


   Seo анализ сайта